Guidepoint Global News Today

A new drug, a monoclonal antibody known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body, according to a phase 2 study led by investigators at the Johns Hopkins Kimme

A new drug, a monoclonal antibody known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body, according to a phase 2 study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy. If confirmed in additional studies, enoblituzumab could become the first promising antibody-based immunotherapy agent against prostate cancer.

Higginbotham will also keep his current responsibilities as senior vice-president for investor relations and financial planning and analysis while Foot

Human Resources and Workforce Management News

Drs. Thabele (Bay) Leslie-Mazwi; Ashutosh P. Jadhav; Justin M. Cappuzzo; Elad I. Levy; Waleed Brinjikji; & Demi Dawkins each ponder what the next breakthrough in acute ischemic stroke therapy should be, with responses ranging from technology & technique...

Investigators suggest adding decolonization to radiation dermatitis prophylaxis regimens.

/PRNewswire/ -- Foot Locker, Inc. (NYSE: FL) ("Foot Locker" or the "Company"), the New York-based specialty athletic retailer, today announced it has appointed...

Xinhuanet and the CCG release report looking at how Chinese cities can improve global communication